ROBUST I Pilot Study, ROBUST I Study, Re-Establishing Flow Via Drug Coated Balloon For The Treatment Of Urethral Stricture Disease

DSC016

Robust I study is a feasibility study for evaluating the safety and efficacy of DCB.

2016-11-01

2018-10-01

2023-04-01

Completed

Early phase I

53

Inclusion Criteria: 1. Male subjects ≥ 18 years' old 2. Visual confirmation of stricture via cystoscopy or urethrogram 3. Single lesion anterior urethral stricture or bladder neck contracture, less than or equal to 2.0 cm 4. One to three (1-3) prior diagnosis and treatment of the same stricture (including self-catheterization) including DVIU (Direct Vision Internal Urethrotomy), but no prior urethroplasty 5. Significant symptoms of stricture such as frequency of urination, dysuria, urgency, hematuria, slow flow, feeling of incomplete emptying, recurrent UTI's. 6. IPSS score of 13 or higher 7. Lumen diameter \<12F by urethrogram 8. Able to complete validated questionnaire independently 9. Qmax \<10 ml/sec Exclusion Criteria: 1. Strictures greater than 2.0 cm long. 2. Subjects that have more than 1 stricture. 3. Sensitivity to paclitaxel or on medication that may have negative interaction with paclitaxel 4. Subjects who have a suprapubic catheter and are unable to complete study required testing, such as uroflowmetry 5. Previous urethroplasty within the anterior urethra 6. Stricture due to bacterial urethritis or untreated gonorrhea 7. Stricture dilated or incised within the last 3 months 8. Presence of local adverse factors, including abnormal prostate making catheterization difficult, urethral false passage or fistula. 9. Presence of signs of obstructive voiding symptoms not directly attributable to the stricture such as BPH at the discretion of the clinical investigator 10. Previous radical prostatectomy 11. Previous pelvic radiation 12. Diagnosed kidney, bladder, urethral or ureteral stones or active stone passage in the past 6 months. 13. Diagnosed with chronic renal failure unless under hemodialysis or has a serum creatinine level greater than 2 mg/dL 14. Use of alpha blockers, beta blockers, OAB (Overactive Bladder) medication, anticonvulsants (drugs that prevent or reduce the severity and frequency of seizures), and antispasmodics where the dose is not stable. (Stable dose is defined as having the same medication and dose in the last six months.) 15. Use of Botox (onabotulinumtoxinA) in urinary system within the last 12 months

{'studyType': 'INTERVENTIONAL', 'phases': ['EARLY_PHASE1'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 53, 'type': 'ACTUAL'}}

2024-03-22